Navigation Links
CoMentis and Anvyl Announce Formation of Alpharmagen, a Joint Venture to explore Nicotinic Modulators
Date:6/14/2013

SOUTH SAN FRANCISCO, Calif., June 14, 2013 /PRNewswire-iReach/ -- CoMentis, Inc. and Anvyl announced today that the companies have agreed to form Alpharmagen, a joint venture committed to discovering and developing novel modulators of the alpha7 nicotinic receptor.

"CoMentis is extremely pleased to be forming Alpharmagen in partnership with Anvyl" said Terence Kelly,Ph.D, CoMentis' President and CEO. "We believe that alpha7 modulators have the potential to become significant therapeutic agents, and we believe that the portfolio of allosteric modulators and the expertise that Anvyl brings provides a unique 2nd generation approach to the established alpha 7 agonist program that CoMentis has advanced."

"We are pleased to be joining forces with CoMentis in creating Alpharmagen" stated David Putman, Anvyl's Chief Operating Officer. The scientific programs are very complimentary and the teams are well matched in terms of their experience. We believe that we can advance compounds quickly into clinical trials."

About Alpha7 Modulators.

The alpha 7 nicotinic acetylcholine receptor is believed to play a role in cognition and modulators of this receptor in the human brain are reported to have shown promise in Phase 2 clinical trials exploring cognitive disorders associated with schizophrenia and Alzheimer's disease.

About CoMentis:


CoMentis, Inc. has its headquarters in South San Francisco. The company is engaged in the discovery and development of small- molecule drugs to treat Alzheimer's disease.

For more information about CoMentis, please visit the Company's website at www.comentis.com


Contacts:
CoMentis: Terence Kelly, President and Chief Executive Officer (650) 869-7600

About Anvyl

Anvyl LLC is based in Irvine, CA and specializes in the development of drugs for serious neurologic and psychiatric disorders. Anvyl's drug discovery approach uses targeted allosteric modulation of ion channels to correct disease.

For more information about Anvyl, please visit the Company's website at: www.anvylllc.com


Anvyl Contact: David Putman, Chief Operating Officer   
(949) 252-9211

Media Contact: daniel hunt CoMentis, 6502106160, dhunt@comentis.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE CoMentis, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
2. Maroon 5 Lead Singer Adam Levine and Shire Announce "The Own It Project," Encouraging Adults with Attention-Deficit/Hyperactivity Disorder to Tell Their Stories Through a National Contest
3. Alexza to Announce 2012 First Quarter Financial Results on Thursday, May 10, 2012
4. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
5. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
6. Misonix Announces New Distribution Agreement For Panama
7. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
8. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
9. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
10. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
11. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... MAPLE GROVE, Minn. , March 22, 2017   ... of Clomipramine Hydrochloride Capsules* USP, 25 mg, 50 mg and ... (clomipramine hydrochloride) Capsules USP. The clomipramine ... for the 12 months ending December 2016, according to IMS ... ...
(Date:3/22/2017)... 2017  Levine Cancer Institute today launched the ... to address lung cancer diagnosis, treatment and survival ... mobile lung unit is the first-of-its-kind to link ... interventions through integrated mobile technology, traditional treatment facilities ... and a lack of public transportation are barriers ...
(Date:3/22/2017)... 22, 2017  Varex Imaging Corporation (Nasdaq: ... renewed three-year pricing agreement with Toshiba Medical Systems under ... tomography (CT) tubes for integration into Toshiba Medical,s CT ... will be effective April 1, 2017. Potential ... are estimated to be in the range of $345 ...
Breaking Medicine Technology:
(Date:3/22/2017)... ... 22, 2017 , ... Drs. Jennifer Houck, Lauren Smith, Heather Johnson and the ... in need of skilled pediatric dentistry in Rock Hill, SC, without a ... routine treatments, including cavities, sealants and fluoride applications, in a comfortable and fun environment. ...
(Date:3/22/2017)... ... March 22, 2017 , ... The Carballo Agency, a comprehensive ... New York metropolitan region, is embarking on a cooperative charity drive with Family ... present, more than two and a half million children in the United States ...
(Date:3/22/2017)... ... 2017 , ... Schneider Insurance and Financial, a southern Montana firm providing asset ... region, is launching a charity event aimed at raising local support for Zoo Montana. ... State, and is home to a broad variety of animals from all over the ...
(Date:3/22/2017)... ... March 22, 2017 , ... The Senior Citizens ... and prevent a default on the federal debt — including the debt held by ... growing concern, ” said TSCL in a letter to House and Senate budget leaders. ...
(Date:3/22/2017)... (PRWEB) , ... March 22, 2017 , ... Sharon Kleyne ... created more than two decades ago to research evaporation of earth’s and the body’s ... promotes better health. Also the host of the nationally syndicated radio program, The Sharon ...
Breaking Medicine News(10 mins):